Construction of anticancer drug incorporated aptamer-functionalized cationic β-lactoglobulin: induction of cell cycle arrest and apoptosis in colorectal cancer DOI
Zhipeng Zhang, Tianran Zhang, Zimeng Li

et al.

Journal of Biomaterials Science Polymer Edition, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 20

Published: Oct. 16, 2024

Nanoscale drug delivery systems that are both multifunctional and targeted have been developed using proteins as a basis, thanks to their attractive biomacromolecule properties. A novel nanocarrier, aptamer (AS1411)-conjugated β-lactoglobulin/poly-l-lysine (BLG/Ap/PL) nanoparticles, was in this study. To unique formulation, the as-prepared nanocarrier blends distinctive features of an chemotherapeutic targeting agent with those protein nanocarriers. By loading cabazitaxel (CTX) onto nanocarriers, therapeutic potential BLG/Ap/PL could be demonstrated. The CTX-loaded (CTX@BLG/Ap/PL) showed regulated release profile acidic milieu, which improve efficacy cancer cells high encapsulation up 93%. However, compared free CTX, CTX@BLG/Ap/PL killed colorectal HCT116 higher at 24 48 h. Further investigation confirms apoptosis by acridine orange ethidium bromide (AO/EB), DAPI staining morphological changes, chromatin condensation, membrane blebbing treated cell through flow cytometry displayed percentages apoptosis. Cell cycle analysis revealed induced sub-G1 G2/M phase (apoptosis) Annexin V/propidium iodide (PI) confirmed induces cells. Overall, study proved had several advantages over drugs promise solution clinical problems associated antitumor systems.

Language: Английский

Construction of anticancer drug incorporated aptamer-functionalized cationic β-lactoglobulin: induction of cell cycle arrest and apoptosis in colorectal cancer DOI
Zhipeng Zhang, Tianran Zhang, Zimeng Li

et al.

Journal of Biomaterials Science Polymer Edition, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 20

Published: Oct. 16, 2024

Nanoscale drug delivery systems that are both multifunctional and targeted have been developed using proteins as a basis, thanks to their attractive biomacromolecule properties. A novel nanocarrier, aptamer (AS1411)-conjugated β-lactoglobulin/poly-l-lysine (BLG/Ap/PL) nanoparticles, was in this study. To unique formulation, the as-prepared nanocarrier blends distinctive features of an chemotherapeutic targeting agent with those protein nanocarriers. By loading cabazitaxel (CTX) onto nanocarriers, therapeutic potential BLG/Ap/PL could be demonstrated. The CTX-loaded (CTX@BLG/Ap/PL) showed regulated release profile acidic milieu, which improve efficacy cancer cells high encapsulation up 93%. However, compared free CTX, CTX@BLG/Ap/PL killed colorectal HCT116 higher at 24 48 h. Further investigation confirms apoptosis by acridine orange ethidium bromide (AO/EB), DAPI staining morphological changes, chromatin condensation, membrane blebbing treated cell through flow cytometry displayed percentages apoptosis. Cell cycle analysis revealed induced sub-G1 G2/M phase (apoptosis) Annexin V/propidium iodide (PI) confirmed induces cells. Overall, study proved had several advantages over drugs promise solution clinical problems associated antitumor systems.

Language: Английский

Citations

0